Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.

about

Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.

Item

http://www.wikidata.org/entity/Q39208487

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Current update of adoptive imm ...... o eliminate malignant gliomas.

@en

Current update of adoptive imm ...... o eliminate malignant gliomas.

@nl

type

Item

label

Current update of adoptive imm ...... o eliminate malignant gliomas.

@en

Current update of adoptive imm ...... o eliminate malignant gliomas.

@nl

prefLabel

Current update of adoptive imm ...... o eliminate malignant gliomas.

@en

Current update of adoptive imm ...... o eliminate malignant gliomas.

@nl

P1476

Current update of adoptive imm ...... o eliminate malignant gliomas.

@en

P2093

Choong Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Jae Min Kim

http://www.w3.org/2001/XMLSchema#string

Je Il Ryu

http://www.w3.org/2001/XMLSchema#string

Jin Hwan Cheong

http://www.w3.org/2001/XMLSchema#string

Myung Hoon Han

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Immunotherapy advances for glioblastoma

Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors

Immunotherapy for brain cancer: recent progress and future promise

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Prospects of immune checkpoint modulators in the treatment of glioblastoma

Cancer immunoediting: from immunosurveillance to tumor escape

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

P304

411-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28357913

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy